0
Skip to Content
Nordic Migraine Symposium 2026
Home
Agenda
Venue & Accommodation
NMS 2025
NMS 2024
NMS 2023
NMS 2022
NMS 2021
NMS 2020
NMS 2019
Contact
REGISTER NOW
Nordic Migraine Symposium 2026
Home
Agenda
Venue & Accommodation
NMS 2025
NMS 2024
NMS 2023
NMS 2022
NMS 2021
NMS 2020
NMS 2019
Contact
REGISTER NOW
Home
Agenda
Venue & Accommodation
Folder: Previous years
Back
NMS 2025
NMS 2024
NMS 2023
NMS 2022
NMS 2021
NMS 2020
NMS 2019
Contact
REGISTER NOW

Combination therapy and switching

Session 4: Pathophysiological Aspects

Anne Christine Poole

General practitioner and headache specialist at Oslo Headache Centre, Norway

Download presentation

Previous

Safety and tolerability, wearing-off

Next

Pathophysiological Aspects

You Might Also Like

Related Embedded Video Item Thumbnail PACAP and VIP
Related Embedded Video Item Thumbnail Impact on patients
Related Embedded Video Item Thumbnail Pathophysiological Aspects
Related Embedded Video Item Thumbnail Societal burden of migraine
Related Embedded Video Item Thumbnail Clinical Implications

Privacy policy

Teva Privacy Notice |Teva Pharmaceuticals

Legal Notes | Teva Pharmaceuticals

Accessibility Statement

Teva code of conduct


Norway, Finland, Denmark: AJO-DK-NP-00128